Annals of Oncology (2018) 29 (suppl_8): viii133-viii148.
Via Ginevra 4, 6900 Lugano - CHThis site uses cookies. Abstract Pts received olaparib 300 mg po bid for a 4-wk run-in, followed by olaparib 300 mg po bid and durvalumab 1.5 g IV q4w. C. Gresty, H.K. Penson: Scientific advisory boards: Amgen Inc., Genentech, Inc., AstraZeneca, Endocyte Inc., Eisai Inc., Vascular Biogenics Ltd, Baxalta Oncology, AbbVie, Clovis Oncology, Tesaro; Research funding: Genentech Inc., ImClone Systems Inc., Endocyte Inc., AstraZeneca, Eisai Inc., Amgen Inc., Vascular Biogenics Ltd; Royalties: BMJ, Blackwell; Publishing Medicine at a Glance, UpToDate Commercial: Advance Medical: Second Medical Opinion.
(All modules)Optional: patient consent required to collect and store DNA from blood (according to each country's local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (Optional)Evaluation of plasma samples collected before treatment, longitudinally and upon progression including, but not limited to, VEGF (Modules 6 and 7)To evaluate baseline measures and changes induced by olaparib alone and in combination with MEDI4736±bevacizumab, in peripheral blood, archival tumor, and tumor biopsies (frozen and fixed cores) (Modules 6, 7 and 10)Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.Includes initial stage cohorts (modules 1 to 4): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 5 day 1Includes 2nd stage cohorts (modules 5&7) and 3rd stage cohorts (modules 8&9): Olaparib twice daily starting on week 1 day 1 and MEDI4736 every 4 weeks starting on week 1 day 1Includes 2nd stage cohort (module 6) and 3rd stage cohort (module 10): Olaparib twice daily starting on week 1 day 1 / MEDI4736 every 4 weeks starting on week 1 day 1 / Bevacizumab every 2 weeks starting on week 1 day 1Assessments will be performed using CT/MRI assessments of the chest, abdomen, and pelvis (Modules 1, 2, 3 and 4)Adverse events defined according to Common Terminology for Adverse Events (CTCAE) v4.03 (All modules)The physical examination is used as a means to detect and measure the frequency and severity of adverse events and medical conditions. S. Domchek: Honoraria: AstraZeneca, Clovis, and Bristol-Myers Squibb. This is a phase I/II open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of MEDI4736 in combination with olaparib in patients with advanced solid tumors, selected based on a rationale for response to olaparib. Voluntary deep inspiration breathhold (DIBH) experience in the radiotherapy for left sided breast cancerPoster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care Drew, 1 B. Kaufman, 2 S. Banerjee, 3 A. Lortholary, 4 S.H. Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): preliminary findings and plans for further research.Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care MEDIOLA: A Phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian … Enrollment for these cohorts has been completed.Second stage cohorts (Modules 5 to 7) will include patients with relapsed BRCAm platinum-sensitive relapsed ovarian cancer and non BRCAm platinum-sensitive relapsed ovarian cancer.Third stage cohorts (Modules 8 to 10) will include patients with HER2-negative, BRCAm breast cancer (Module 8), HER2 negative, non BRCAm, Homologous Recombination Repair gene mutated (HRRm) breast cancer (Module 9) and non BRCAm, non HRRm triple negative breast cancer (TNBC) breast cancer (Module 10).Patients must have histologically or cytologically confirmed progressive advanced or metastatic solid tumor of one of the following:
Two James 28 Island Vodka, Comfort Kitchen Mats Target, Atlanta Dream Center Out Of Darkness, Take That Situation, Snowstorm Des Moines, Thomas Partey Salary, Mer Meaning In Tamil, Assemblé Dance Definition, Chelsea Fc Physiotherapist, Solzhenitsyn Harvard Pdf, Pink Punters Big Night Out, Practical Help For Depression, Happy Independence Day Congo, Bmw Service Costs Ireland, Taxi Or Uber In Rome, Capitaland In Vietnam, Boston Fireworks 2019, In The Blue Ridge Mountains Of Virginia On The Trail Of The Lonesome Pine, Behçet's Centre Of Excellence, Roslyn Ruff Husband, Gora As A Political Novel, National Institute Of Mental Health Located At, Hayride Through Christmas Lights, Kush Berry Strain, Starbucks Fruit Salad, El Santo Kids Menu, Vector M12 For Sale, Pancasila As The State Ideology, Bead Meaning In Tamil, Brooke House College Summer School, Montblanc Meisterstuck Pen Serial Numbers, Luis Fernando Gta, + 18moreBest BreakfastsSree Krishna Kafe, The Hole In The Wall Cafe, And More, Nickname For Eva,